A stimulant's reward only formed when rats got high in company, and two peptides decided whether it stuck.
Researchers at the Medical University of Lublin gave rats mephedrone, a stimulant once sold as a "bath salt," and ran the standard test for whether a drug feels good: conditioned place preference, where an animal comes back to the spot where it felt the drug. Mephedrone on its own did not build that preference. Mephedrone taken in a social setting, alongside another rat, did. The reward needed company. The work appears in Genes, Brain and Behavior ↗.
That social requirement pointed the authors at the brain's two main social-bonding hormones, both of them peptides: oxytocin ↗ and vasopressin ↗.
What the peptides did
Being conditioned in a social context raised the rats' blood levels of both oxytocin and vasopressin. Mephedrone then selectively knocked the oxytocin rise back down, leaving vasopressin up. Inside the brain the picture flipped by region: mephedrone increased vasopressin V1A receptor gene expression in the hippocampus and oxytocin receptor gene expression in the nucleus accumbens, the hub the brain uses to tag things as rewarding.
Social context alone also quieted the general chemistry, lowering baseline dopamine, serotonin and noradrenaline. In the classic non-social test mephedrone had raised prefrontal dopamine, the usual signature of a stimulant high. Adding company erased that dopamine spike and swapped in the peptide signal instead.
Two off-switches pointing opposite ways
The interesting part is how the team then cancelled the reward. They did it two ways, and the two ways run in opposite directions.
Giving carbetocin, a drug that turns the oxytocin receptor up, abolished the social reward. So did SR49059, a drug that turns the vasopressin V1A receptor down. Push one receptor higher or pull the other lower, and the same preference fails to form. Meanwhile the manipulations that should have mattered on a simple reading did nothing: blocking the oxytocin receptor with L-368,899 left the reward intact, and injecting vasopressin into the body rather than the brain had no effect at all.
That last null is the tell. Peripheral vasopressin was inert, so whatever these peptides are doing to social drug reward is happening centrally, in the brain, not in the bloodstream that a blood test would catch.
What it is and is not
This is a rat study of one stimulant, and the receptor readouts are gene expression rather than counted protein, so the mechanism is a map, not a measurement. It is not a treatment, and mephedrone is not a therapeutic. What it offers is a wiring diagram: the reward that recreational stimulants get from being taken socially appears to route through oxytocin and vasopressin signaling, with the two receptors acting as opposing levers on the same behavior.
That pair sits on peptidemodel as marketed drugs and live targets. Oxytocin is the labor and bonding hormone (Pitocin, Syntocinon); vasopressin is the water-retention and blood-pressure hormone (Pitressin, Vasostrict); carbetocin is a longer-acting oxytocin analog used after delivery. Their receptors, OXTR ↗ and AVPR1A ↗, are the two knobs this study turned. The finding worth keeping is that turning them opposite ways landed in the same place, which is a hint that social reward is not a single peptide's job but a balance between two.